Are new technologies translatable to point-of-care testing?

Lancet. 2017 Dec 23;390(10114):2765-2766. doi: 10.1016/S0140-6736(17)33301-9.

Authors

Danielle Bury¹, Pierre L Martin-Hirsch², Francis L Martin¹, Timothy P Dawson³

Affiliations

¹ School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Lancashire, Preston, UK.
² Department of Gynaecology, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Trust, Preston PR2 9HT, UK.
³ Department of Neuropathology, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Trust, Preston PR2 9HT, UK. Electronic address: timothy.dawson@lthtr.nhs.uk.

PMID: 29303719
DOI: 10.1016/S0140-6736(17)33301-9

No abstract available

Publication types

Letter

MeSH terms

Humans
Inventions
Magnetic Resonance Spectroscopy
Neoplasms / diagnosis*
Point-of-Care Testing*
Spectrum Analysis
Translational Research, Biomedical
Vibration